SGMO - Earnings call transcript Q1 2020 | Sangamo Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. And welcome to the Sangamo Therapeutics Teleconference to Discuss First Quarter 2020 Financial Results. This call is being recorded.

I will now pass you over to the coordinator of this event McDavid Stilwell, Senior Vice President of Corporate Communication and Investor Relations.

McDavid Stilwell

Good afternoon. joining for you thank us today. And

Stephane this of Bettina Chief the me Chief Head Officer; Financial of afternoon Adrian Development; Medical Corporate including Chief on members several Executive Business Officer; Chief Lee, McClung are Research call Sung Head Sangamo Woolfson, Cockroft, Macrae, of Strategy; this Sandy With Boissel, Mark senior , and team, management and Officer Officer.

section the in can be Events found our Investors our and from under Media page. corporate presentation Presentations Slides the website, and at sangamo.com,

call forward-looking clinical cost certain statements regulatory obtain pipeline our limited and diseases such relating This includes current candidates, of statements expectations. to availability plans and treat therapies, develop, our include, to Sangamo approval the regarding timing, These timelines for to of Sangamo's product to for not genomic trials and to medicine but benefit commercialize the and collaborators and and pandemic are trials ability and potential to for and statements our therapies COVID-XX our clinical data, operational certain impacts technologies these expectations manufacturing use our patients, our performance and to regarding therapies, to opening and the develop facilities, of for the conduct building timelines plans our and evolving clinical financial share the resources. provide collaboration, financial to and potential

Actual results may differ substantially from what we discuss today.

Form our documents recent on are statements annual In and quarterly in of file certain we Form to subject XX-K. XX-Q and in and the not our risks Commission, addition, filed that Securities performance report specifically most are discussed that these future and report with uncertainties are guarantees today, on Exchange

measures We the for and information, this our today's isolation GAAP considered performance This as reconciliations no required substitute made applicable as comparable press financial GAAP in except we measure measures. discover are discussed undertake believe The this such future and On to forward-looking The on duty or this measure to included stated is helpful statements are past a understanding comparable we financial column is meant our is the law. GAAP available of our website. under be and on not of non-GAAP non-GAAP in which as potential measure. update call, results. this today release, to in date,

like the And turn now, over I'd Sandy. to to call

Sandy Macrae

Thank everyone the you, And McDavid. good afternoon on to call.

in when one to talk you COVID-XX about I Today, Sangamo the all we of team circumstances. business offices, headquarters in California. all make to Brisbane, Typically, our many the every these together home with come adaptations to the boardroom the due executive our the are of we've unprecedented quarter, in we're pandemic, to in had

Last neurological At position. we've business, collaboration regulation Sangamo, agreement our with other together strong gene last impact are and of to for in were neuromuscular Alzheimer's month, the pandemic disease, to of Parkinson's very pleased we a Biogen therapies the we disease, worked months, to announce very the I diseases. and two on develop that any believe closing minimize over our

$XXX additional million Biogen the an We fee in have sale proceeds the stock upfront million from of $XXX from and license received payment.

including programs addition sheet, balance Biogen to the March our the on financial we for $XXX of BLA believe development this reported SB-XXX have we to filing multiple and the strength million wholly-owned beyond received that important million on potential in our hemophilia from resources A. for cash XXst partnered $XXX and With we in the execute milestones

the Sangamo to welfare, has In responsibly while and business. response safety employee COVID-XX, prioritized advancing

middle March, government in authorities from we non-lab the home. asked the shelter-in-place guidance of work to all employees Following the from

achieving employee and manufacturing to protocols social and while work continue implemented and safety also critical guidance. modified lab to operations We protecting updated distance research safety

We're in focusing staying patients the activities constraint with of also on prioritizing system we as sites trial. including not while partnered programs. the business on strategically close in trial labs, activities track, conducting projects keep to cautiously, safety to unnecessarily protect are contribute the the in clinical healthcare communication the our the to so for In research to

We will be headquarters this end continue AAP and optimistic with of manufacturing our our be facility to the operational Brisbane by year.

our manufacturing and We units California, in to also France Brisbane, in expect the XXXX. be end cell open by therapy Valbonne, of

and activities. our keeping contact we’re do with with our manufacturing regular not anticipate now Furthermore, in delays partners, CDMO as COVID-XX-related any of

partnerships, access challenges An deals such technology, the environment, to new Sanofi, well we both already the of is Despite have Mogrify, with potential Takeda. new to as developing announced collaboration, with the technology as local has to that source. established continue serve of as partnership an actively the Gilead, important renewable an a out-licensing inbound Pfizer, that conversion Cambridge UK we company, license current recently pursue inbound cell ones as our Biogen, example exclusive cell

This CAR-Treg cells. aims therapies shelf regulatory Under develop our proprietary derived protein, using CAR-Treg current cell will use iPSC therapies. allogeneic we Sangamo technology agreement the terms T develop complement to Mogrify’s agreement, of finger zinc the this license diversify off options, allogeneic cell and to as engineered, our gene efforts conversion

the that accelerate believe renewable manufacturing potential novel therapies. We source, cell this development and of exciting to the Treg collaboration has

also are our on outlicensing discussions We opportunities. continuing

in to select clinical companies bio resources programs a treatment that a is for where our expertise As pharmaceutical new more or development feasibility may believe patients. advance in area with reminder, strategy therapeutic collaborations situations of and development the enable financial we rapid and partner's to partnership

Sangamo we some strategic partner. the team, transitions on my evolution a recent want Before are I I you over our the call update direct as and part reports advance development that turn to amongst of clinical the to natural of

and R&D, corporate and business perceive Presidents and the look has we’ve few as we Chief and Vice our Officer, alliance latest capabilities, now appointment, lead executive and planning, expertise years joined commercial development. McClung as need Business manufacturing, and commercial, to in added Sangamo, the Mark for Executive legal, to future last leads for finance development While the strategic management

development competitive require integrating a including insights that Mark as and clinical and successful late career deep has development a commercial highly and a knowledge into physician areas stage disrupted result the occurs scientific have programs. care and leading innovative a products patient of tightly product organizations distinguished Amgen, and include therapeutic of where GSK, standards Onyx

largest resulted contribution in many His recent as Stephane’s deals our end and July EVP Strategy is acquired to we leave know years. France, Corporate Boissel, entrepreneurial the vision and to transaction, endure Biogen ever Sangamo joined Stephane of at of a led CEO. the XXXX the cooperation for of biopharmaceutical one on return an impactful energy plans in after industry. Stephane Sangamo will will which sign Sangamo preclinical Stephane Sangamo project. in TxCell, which

the Medical Chief Bettina. will With turn over call that, our to I Officer,

Bettina Cockroft

afternoon. Good

plans, have light protect and of very to enrolled In partners we the patient all our continued data. establish our of procedures. every with trial appropriate closely patient, pandemic, as clinical safety we Sangamo the COVID-XX integrity our of After sites plan devise study, well the each is for individualized trial established to in IRBs working as sites a to with work

appropriate cases, still trial clinical redirect pausing and time capacity are may trial or not until be an site some sites, patients. reducing dosed patients to trial have been partners and being is identified. COVID-XX screened In other enrolled clinical but resources At work to

be this do so as we procedures efficiently with quickly addition site trial to implementing able suitable clinical in resume enrollment. new patients possible. for to operations To are keeping this, may to and partners the as that close now, as our and potential In to our as that subsides, COVID-XX situation, we're adapting operations we'll contact continuing be crisis identify

with further [ph] time optimize this some track to we're agencies. collaboration regulatory our engage programs. with spaces clinical working also our cases, closely using also of In to processes and joint the development partners operations We're

or some Turning X/X A the therapy. end operations last ALTA fully enrolled to to the along the commencing PF-XXXXXXXX gene IND transferred of with We of now clinical year. study Pfizer hemophilia at updates, with SB-XXX Phase

opportunity together first the provide closely cohort. with year the to an results that ASH target, identify at to dose the working continues the Pfizer XXXX. to HX high XXXX dosing appropriate in on Phase Pfizer expansion X in the study from update were an patient shared We're this

Pfizer lead-in due to disruptions X Pfizer updated schedule us trial course. informed that COVID-XX have clinicaltrials.gov additional minimize to ongoing protocol continues study Phase Phase patients the on updates to in with any due recruit provide to potential study. they plan is pandemic and and recently into X Phase X working to the the the the

initiate to our the We’ve into therapy, Fabry now disease. STAAR study, first for to waiting the for Moving gene patient. are dosing enrolled wholly-owned and and ST-XXX time successfully appropriate patients we a safe and screened

edited levels, of beta enhancer conjunction our expressed BIVVXXX for ST-XXX of specific gene, induce gamma ST-XXX beta strong may the the hemoglobin if for we're thalassemia, are was erythroid cell disease. or fetal and sickle In is therapies patients levels This with Sanofi, of for and to fetal the gene. two synthesis evaluating globin of gene knockout BCLXXa cell for thalassemia high by beta a substitute it hemoglobinopathies encodes In globin. which achieved enough impaired hemoglobin. BIVVXXX repressor designed the absent gene-edited both partner at

THALES evaluating ST-XXX enrolled We patients for into thalassemia. study have and five dosed the beta

down increased patients abnormal that In cell and disease and crises synthesis regulate disease, sickle results painful fetal hemoglobin the sickle the other in with cell hemoglobin sickle features. functional hemoglobin provide help may

last been PRECIZN-X in first disease into and BIVVXXX also dosed year. the has sickle cell patient Sanofi study evaluating enrolling the patients

of enrolling when will the treated patients two analyzed. and will have Sanofi New from follow-up. THALES additional a be patients meantime analysis of has sickle collected studies into PRECIZN-X in number study. cell until the data thalassemia been beta data the continue the the patients shared studies will study study’s sufficient both the the be in and accumulated No

time We a for from at data date. appropriate these both present will to look future studies an

regard to a are closely potential like programs that by monitoring with conclude we few COVID-XX. by impact I'd addressing to

HLA-AX transplantation. STEADFAST additional make the cell therapy our kidney We to Phase X/X regulatory progress first-in-human TXXXX evaluating with mismatched study, for in approvals CAR-Treg continue

We patients XXXX. expect study to dose in in this first

a a an anti-CDXX product allogeneic being trial. on us by of cell delay a COVID-related CAR-T now Kite, to to for the and initiation Gilead is that Moving KITE-XXX, the Kite company. there has informed clinical potential KITE-XXX developed

overview the Sung an for I results. call will now turn financial the Sung? the of over

Sung Lee

and afternoon, Bettina, you, Thank everyone. good

pleased share XXXX. same quarter net for million million per We're our the million, or loss XXXX. We of period a per The of share, share $XX.X to XXXX. in first $XX.X net $XX.X were for million period same to compared $X.X compared $X.XX to $X.XX the results a the for in revenues or financial loss of recorded

which and therapeutic in operating manufacturing to operating Company's headcount and capabilities. million Non-GAAP expenses, growth exclude expenses. related primarily support million facilities expansion compensation to advancement compared of Sangamo's $XX in the the to pipeline were XXXX. to overall increase was The $XX.X Turning expenses

million Moving $XXX cash ended the with to and equivalents in the quarter We balance securities. cash, marketable sheet.

and stock of we Following the QX, from Biogen received from sales upfront of license million the fee. end $XXX the

earlier, mentioned SB-XXX A. Sandy the important we As have BLA hemophilia to the milestones, sheet take potential filing strength through of first us R&D balance for we believe including the for

XXXX to guidance. year full Turning

guidance We expense our anticipate time, million guidance. are At range expect operating $XXX to previously stock excludes of financial impact we $XX in negative reiterating in of do estimated and any from be expense, million million $XXX to shared expense COVID-XX financial not to compensation the operating non-GAAP this material which XXXX. our

will We situation the capital. provide In be good monitor continue in and future. to continue will we stewards the an the of to meantime, update

closing I'll to for now turn remarks. it Sandy back

Sandy Macrae

you, Thank Sung.

protein highly of which the sheet our biopharmaceutical strengthened another vote This and differentiated medicine with significantly zinc yet our an the milestone a represents confidence important closing of both company. finger agreement, platform in from top quarter Biogen genomic balance marks

observed in confidence in strength, these to partnerships our due the development our our in that return discussions, sheet we've our proven established and a this to continued kept laboratories, crisis in forward, crisis plans from to times, subsides. unprecedented sites. sense resilience our investments to moving tremendous great technical our and and the research rapid continued as facilitate infrastructure, We has weather with of ongoing more including And employees. and COVID-XX operations normal to balance ability business strategic I’ve business our trial clinical this business and adaptiveness In our feel operations

for ready are questions. we Operator,

Operator

question comes with from Thank Instructions] Our you. Maury [Operator Jefferies. first Raycroft

Your open. line is

Maury Raycroft

for Thanks questions. everyone. my taking Hi,

just is on question First hemophilia A.

steroid Phase use, the to talk design the it's you with So, are take trial what at going posted study? more about including estimates dose, enroll on to this how X to can and clinicaltrials.gov, the time, long

Sandy Macrae

thanks Maury, your question. for

ahead design can control respect of have imagine And and to of give the the Pfizer, relationship they the trial. under told announcements the is Phase we trial us all moving you X planned. As and about will them. that trial communication that as Everything with far so to want guides they the

Pfizer with and trials are partnership impact the available the where they're can of advantages where COVID the of One the that is take a our is less. global patients organization to

with the them year more look forward progresses. you information to So, sharing we as

Maury Raycroft

had initially guys Understood. you patient mentioned And more for expected. failures then, Fabry, you screen that had before than you

Just those been implemented criteria you’ve changes, and wondering helping? if enrollment have

Sandy Macrae

Bettina, to talk that? would you be to able

Bettina Cockroft

Yes, of course. Hi, there.

And So, communication the we some implementing Fabry have patients into as actually we enrolled today, been you have will changes. noted looking from at have study. the

we COVID but dosing timing, we assessing in for Now, have patients an been as first of inclusion the course, study. the best subjects, to of pandemic, have has uptake and that resulted during the into the had very-cautious

Sandy Macrae

you changes made that? and facilitated you’ve protocol to And that have the do permitted Bettina, feel the that

Bettina Cockroft

absolutely. Exactly,

Maury Raycroft

come part initial plans that plans. the was conduct could just the just last reduction later a then, one Maybe to talk or you -- And Okay. more have study quick biopsy you for in could GbX if this on formalized in on? renal of if about wondering

Sandy Macrae

our for GbX renal discussed the and for plans haven't We biopsy.

you can about a imagine, a biopsy. benefit is and risk that patient As issue of complex renal the

We of that to appreciative renal are are for of incorporating biopsy aware into get are Fabry, by with and the as it very quickly possible quicker our to plans. and as FDA registration the make allowing patients medicines very trying

Operator

Barclays. comes next Our question Wang from of Gena

line Your is open.

Gena Wang

Thank you questions. questions. I have for my two taking

update, disease. The first second regarding A and Fabry hemophilia is regarding question

I XX update, hemophilia understand importance the So of A months emphasized Pfizer data.

several the say Given fair it mention on And a did last this be is Fabry good follow-ups to you disease, enrolled will likely patients. show year data? you ASH, for timing to XQ

year? first many And how patients? the initial this also, could of is remind to us still Fabry next present data possible beginning for Also, wondering you Just dose disease?

Sandy Macrae

rest warning the at Bettina A, moves first their about we their XX-month rate haven't take same only this will take that but next -- first it just Let time quarter out yet. are and dose me I majority the hemophilia the the coming unfortunately question throughout if patients and of very talked that's passing do reach to now could patients of and before on you point, But, the world of and patients you to XX-month weak the for point. the the the

deal part the for Pfizer communications will all lead transition as So, of a like this.

will I a has it company will frustrating. hands communications, with share when which this that that you all and is Pfizer's agree is company You lead they decide that. they that all. and will in have know data be single But, leads they to

you can Fabry, our Bettina, in talk And please? about enrollment

Bettina Cockroft

Yes, absolutely.

completed concerned, going as far So, your as address showing Fabry is be our efficacy we we sure after the to we to last we're safety high. we've to question set want data We planning that terms make of three the escalation in of present medium ST-XXX. which low, in protocol. across can said data dose cohorts first, that we have test, doses to that a mature and have represent were And and

we've AAVX protocol through can to learned made SB-XXX future. say amendments is take guidance hemophilia specific program and A we've will FDA learnings appropriate We Fabry those lot also I a our disclose point account. at the and into in program doses the an to What about

in to on So, further we forward look future. the updating this

Gena Wang

Okay. enrolled? How patients many already have

Bettina Cockroft

I think not... we’re

Sandy Macrae

we’re exactly, have patients not disclosing that. we Yes, But, enrolled.

the you have to from dose sure to sites, choose we make service patients sure overstressed. interest a us And to is they're wisely come and the I'm it's monitoring. because the to we have We that patient. of health that first agree for not need and that when in choosing safe would matter want just will

Gena Wang

you. Thank

Operator

you. Thank

Ijem Whitney Our next question from Guggenheim. of comes

Your open. line is

Whitney Ijem

taking up for questions. Fabry. follow the I Thanks guys. on Hey, to wanted

any of more enrollment, you facilitated if learn curious were that could So, second I And the adjusted guess entry we us kind the the color on then, is just that criteria question can there. give first, on endpoints.

guess, you reflected the you clin-trials? safety XX mean are present have I kind that what does of in data complete on mentioned, months won't until is that’s follow-ups a You set. tracking, you that and or data follow-up what terms of endpoints

Sandy Macrae

for Each what not look to of things into understanding adjusted antibody criteria first were So, right ours therapy her the question. you patients They criteria, our Fabry your done put things. that into The an and learn are we a the like like, Whitney, a were patients more thank time gene company we few in team job for the have like from patients goes and patients. And available. study. disease, simply Bettina new excellent understanding about

high is of the we dose that the we've -- each have said, low, complete, see about and until medium it's as When cohorts, through data of you. what has we share them mean each the won’t the with we will the And cohorts. we biochemistry as as from soon dose talk gone Bettina study

right we'll to look be results at you able will including be that biopsy. some share hope the additional and absolutely follow-on of to biochemistry to there You're patients’ we But, initially the parameters, intervention. our data in that talk about

Whitney Ijem

it. Got

of biochemistry. is cutoff? I there? three months Just quick you six at follow-up data? dose what's endpoints, want biochemistry that kind like see in What And higher guess, have the the announcing you guess, threshold are at it looking terms I to the to of months or particular of the

Sandy Macrae

described We haven't that.

for speaking You've you us been long to cautiousness stabilize. in too and soon waiting for with our time, results the understand and a

we community. inform inform and can, you most the most as So, patient

Operator

Baral of Instructions] next Cowen. [Operator from Our question comes Ritu

Your now line is open.

Ritu Baral

you the I optimized I'm and said, other different question. Fabry how about cardiac, unmet And been as criteria in you there's the patient more need there to are your want specific take Can’t molecule other aspects that Fabry another some kidney going unmet in have and proving maybe as stab the those to be conditions? key for talk the to other kidney? therapies Fabry, about think the not need myself. across help therapy patients. and you you unmet at they interested about need gene organ may of manifestation disease, systems, versus the and in initial small think disease, in companies effect screening understand Fabry addressing the you in like gene Can you

Sandy Macrae

kidney Bettina Fabry. the learned us therapy from I'm is the patients pharmacology, to us biopsies, can talk to with with in the to this But, we’ve few So, about to And time has let we of first learned good the few into moment. first gene effect moved any levels. those. you first a the plasma And imagine

the So, premature to is last thing three do. We, to companywide me benefits I that to the patients right things for it like medical about need. still not or that? it's take still them. week think talk Fabry they declare Zoom clear patients had week there's talking are Bettina, bother in conversation, what And need, Fabry the would and to be a all receiving would you that the before, a part But

Bettina Cockroft

in of at address field we've is of the affected. should conversations Yes, Sandy, exactly its And point this primary other with Fabry said, course. Phase highlighting, point at our a what trial, experts kidney safety in and this trial, tolerability cardiac We ST-XXX. out of objective many you’re X/X and had and being this to point organ is

to with we from need. of moving as turn on we focus SB-XXX. some sense see unmet we that moving And organs learn, saw tolerability AAVX address the gene based on to the therapy so, we as more that forward make hope the there and safety And

Ritu Baral

regulatory are meetings regulatory you give Treg you mean, meetings agencies mentioned, you moving guys the Sandy, color into moving some that? the what to is you in bandwidth then, with COVID. a us engage And that of have obviously Can you additional sort you of clinic. going elaborate little forward new that are you Could Fabry with mentioned it. regulatory into on some I around as moving is need? clinic, with the Got might activities, you

Sandy Macrae

You So, are COVID? with make question? agency sure having can meetings I around the I are agencies with additional we your understand asking, regulatory or

Ritu Baral

I'd or initially in quarter regulatory had the say, some streams on may I work changes around love the you how engage programs, there with have program? you. But, next around two the sounded been with like more COVID, to misunderstood have know regulatory No, what meetings opportunity not comments on with but planned, It COVID. to are in your agencies or

Sandy Macrae

pass on comments. to And this Bettina So, going this I'm I'm going out Bettina? make then, help to general to to more one.

Bettina Cockroft

Yes, absolutely.

we and where earlier So, absolutely you're today. the this agencies, TXXXX are on our especially TXXXX, various it ones What various focusing picked engaging study. specifically up you've European in with that initiating We’ve are right. mentioned mainly is we the we're regulatory on countries

we what of are of through still those And study. But, a study during receiving that hard. we're the this are pandemic. regulatory Many feedback, processes even And that's in. is so, approval all for engaging lot going that exactly agencies working

Sandy Macrae

had in conversation comments work more about basis, studies modifications then, general agency, on a been particularly and and to are having I to Board specific very impacts a clinic agency on if the of on ongoing is. conversations, COVID have has there what the your program. protocol, any in that. about Bio agency, regular a that’s modifications but hasn't about the to have general how FDA how And basis to make Sangamo had those with our question have understanding -- companies the sit with data, more some we not the we

Ritu Baral

be forward? you Sandy, opportunity. be versus question, talk Sangamo appropriate current -- Can sorry. the last it. most other taking now in programs The you your them would may think that a also you partnership you to that partnership mentioned lineup considering Got partnerships for

Sandy Macrae

that others what that ago, we've pipeline. think Sangamo one tau things the in of that a while the XX But And of There and current there are Biogen, the you the the that X targets knew of existing also to space to CNS been none our in the within if So, with there for part we speaking the synuclein assets other were are in. portfolio, products, at that were we've genome, of you are Sangamo's. not partner have for all further was you could -- but things us our those three happened ahead many spoken of. are no we the months, of even go other within Alzheimer's moment that for partner are that plans think interested pipeline aware you

Ritu Baral

it. helpful. the questions. for taking Thanks Super Got all

Sandy Macrae

you very much. Thank

Operator

Thank you.

Jim of Securities. Fargo Our next out from Birchenough Wells question comes

Your line is open.

Yanan Zhu

for is the taking Hi. questions. Thanks dialing Jim. Yanan This for in

first on in Alzheimer's Biogen. you whether program IV also, decided Wondering, might intraperitoneal that the have or program, is route the collaboration question type a there secondarily, with And what optimal be it's delivery first, So, you a that injections? when for will communicating be of around? first nomination milestone, the a Thanks. you example, just So, IND, so think be? milestone of any wondering or that the for a timeline, candidate a might sense

Sandy Macrae

to So, bit will wonder be I it comment delivery routes this But, we've communication. a said for like if Stephane of make and milestones. what Pfizer, could on Adrian Biogen

perhaps So, Adrian first?

Adrian Woolfson

talking the route thanks we new, will referring to be derive directed We delivery And for ASGCT some week, evolution just capsid are this on do I Sandy. question. our to about using But we'll disclosed that if will -- you in that. the to example, attempts of Thanks, we’ll and understand Yes. over serotypes that it for say, haven’t so leave our, Biogen library. to and

got considering delivery wouldn't range that will be programs that. to comes specific more that. out program the we've a at work obviously Biogen. that different of of fact But, anything active we're than want So, to point, of those this routes. And But, doing relevant an it's be

Sandy Macrae

by… presentation the And that's

Adrian Woolfson

where of using different sites serotypes. range Sandy, with libraries and made peptide parental different we a capsid by insertions these insertion right, That's Yes.

Sandy Macrae

the way is contract the And constructed.

Stephane Boissel

only So, Sandy, we the ago. days yes, weeks a have the deal only closed a we few few collaboration Biogen on-boarding ago. the of And

make get we to Biogen. the as the before are committee timeline meant meet we on for the staying on products So, to can any little work need to collaboration for really be update to the various patient a we started to with

Sandy Macrae

first of was meeting But successful the I very hear. shot

Stephane Boissel

a had And It of kind very was. well. success, virtual to setting XX%, we totally bizarre like or as a on Zoom despite, combination employees it it start on and was real the because unique with. something Sangamo setting bizarre Biogen again, was Oh, phone of and despite

Jim Birchenough

just very regarding Fabry program. Thank you. That's then, questions And helpful. quick disease two

you. gene initial cohort, what's starting Just your positioning achieve terms can low the dose biomarker other data similar approaches? you against wondering or enzyme enzyme your level? what at is Thank regarding in therapy recently? in And impression AAV cohort, of And competitive presented that from dose was Fabry think whether to your higher

Sandy Macrae

So just in are comparing against, your clarify Freeline. Freeline of second Are bio, the -- part I you this question? saying you a can or who or

Jim Birchenough

AAV, Freeline. yes,

Sandy Macrae

clinic. And are the helpful dose, final us take dose the compare So, with let that different answer doses. into And be get in we I of clinical therefore, would results. can complete us I looking it to for to dose me something if the that pleased and patients. our We're see these. showing animal clinic why the the forward going and both with low results. you can the our versus is until into think the results don't study have all to study. see design we're matters pleased Freeline’s low of none because we we wait claim that of And And that's at we're three all

emphasized, Bettina safety. is as And about study the

will because this at that start looking compare is we'll be safe efficacy. looking have we as be cardiac at liver can only be So, making enzymes, that then enzymes. you to sure when as on We'll possible, you

Jim Birchenough

Sandy. Thank it. very Got That's helpful. you,

Operator

at further this to Sandy closing question I'd call remarks. Thank Macrae like showing you. to back time. no over the I'm for any turn

Sandy Macrae

interest. Thank virtually. you this all all your for you for doing Thank

and in year And progresses. virtual to with Sangamo forward to a as proceed able our at with fortunate we very are staff lab be the look you the to laboratories. We team sharing results more

Operator

does today's conclude this gentlemen, Thank and you participating. Ladies conference. you. Thank for

a disconnect. day. great You Have may all

Sangamo Therapeutics (SGMO) 11 May 202020 Q1 Earnings call transcript